FDA approves ‘game-changing’ pancreatic cancer drug

The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease. The drug, Revolution Medicines’ Rasonque, or daraxonrasib, was approved for patients with advanced pancreatic cancer who have already tried a prior treatment, such as chemotherapy, the agency said. In a late-stage clinical trial of 500 patients, people who got the drug lived about twice as long — 13.2 months, on average — compared with people who got chemotherapy. Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center...